- Home
- BYM vs ATAI Comparison
BYM vs ATAI Comparison
Compare BYM & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BYM | ATAI |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.2M | 1.4B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BYM | ATAI |
|---|---|---|
| Price | $10.84 | $4.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 60.2K | ★ 3.2M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.49% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,018,000.00 |
| Revenue This Year | N/A | $943.18 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 811.78 |
| 52 Week Low | $9.30 | $1.15 |
| 52 Week High | $11.77 | $6.75 |
Technical Indicators
Market Signals| Indicator | BYM | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 34.33 | 47.85 |
| Support Level | $10.76 | $3.88 |
| Resistance Level | $10.97 | $4.72 |
| Average True Range (ATR) | 0.09 | 0.25 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 13.96 | 35.71 |
Price Performance
Historical ComparisonAbout BYM Blackrock Municipal Income Quality Trust of Beneficial Interest
Blackrock Municipal Income Quality Trust is a closed-end municipal bond fund. Its investment objective is to provide current income exempt from U.S. federal income taxes, including the alternative minimum tax. The trust invests in various sectors such as transportation, utilities, health, education, corporate, housing, and others.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.